Journey Medical Shares Retreat After Annual Revenue Misses Wall Street's Estimate

Dow Jones

03/26

By Elias Schisgall

Shares of Journey Medical fell after the company reported 2025 revenue that missed Wall Street's expectations due to falling sales for Accutane, treatment for severe cases of acne

The stock was down 7.7% to $6.30 in post-market trading on Wednesday, falling deeper into negative territory after closing the regular trading session off by 1.2%. Shares are up 5.4% in the past year.

The commercial-stage pharmaceutical company reported a full-year loss of $11.4 million, or 47 cents a share, compared with a loss of $14.7 million, or 72 cents a share, in 2024.

Revenue rose to $61.9 million, up from $56.1 million in 2024. Analysts polled by FactSet were expecting $64.6 million in revenue.

Growth in revenue was driven by inaugural sales for and the commercialization of Emrosi. That was offset by competitive pressures on Accutane revenue, which fell by $6.5 million.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

March 25, 2026 18:09 ET (22:09 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2622000415"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622000415\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622000415?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 06:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622000415","market":"us","top_or_hot":-1,"title":"Journey Medical Shares Retreat After Annual Revenue Misses Wall Street's Estimate","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Journey Medical fell after the company reported 2025 revenue that missed Wall Street's expectations due to falling sales for Accutane, treatment for severe cases of acne \n</p>\n<p>\n  The stock was down 7.7% to $6.30 in post-market trading on Wednesday, falling deeper into negative territory after closing the regular trading session off by 1.2%. Shares are up 5.4% in the past year. \n</p>\n<p>\n  The commercial-stage pharmaceutical company reported a full-year loss of $11.4 million, or 47 cents a share, compared with a loss of $14.7 million, or 72 cents a share, in 2024. \n</p>\n<p>\n  Revenue rose to $61.9 million, up from $56.1 million in 2024. Analysts polled by FactSet were expecting $64.6 million in revenue. \n</p>\n<p>\n  Growth in revenue was driven by inaugural sales for and the commercialization of Emrosi. That was offset by competitive pressures on Accutane revenue, which fell by $6.5 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2026 18:09 ET (22:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Journey Medical Shares Retreat After Annual Revenue Misses Wall Street's Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJourney Medical Shares Retreat After Annual Revenue Misses Wall Street's Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-26 06:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Journey Medical fell after the company reported 2025 revenue that missed Wall Street's expectations due to falling sales for Accutane, treatment for severe cases of acne \n</p>\n<p>\n  The stock was down 7.7% to $6.30 in post-market trading on Wednesday, falling deeper into negative territory after closing the regular trading session off by 1.2%. Shares are up 5.4% in the past year. \n</p>\n<p>\n  The commercial-stage pharmaceutical company reported a full-year loss of $11.4 million, or 47 cents a share, compared with a loss of $14.7 million, or 72 cents a share, in 2024. \n</p>\n<p>\n  Revenue rose to $61.9 million, up from $56.1 million in 2024. Analysts polled by FactSet were expecting $64.6 million in revenue. \n</p>\n<p>\n  Growth in revenue was driven by inaugural sales for and the commercialization of Emrosi. That was offset by competitive pressures on Accutane revenue, which fell by $6.5 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2026 18:09 ET (22:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DERM","symbol_name":"Journey Medical Corp","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2622000415","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622000415","pubTimestamp":1774476540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Journey Medical fell after the company reported 2025 revenue that missed Wall Street's expectations due to falling sales for Accutane, treatment for severe cases of acne. The stock was down 7.7% to $6.30 in post-market trading on Wednesday, falling deeper into negative territory after closing the regular trading session off by 1.2%. Shares are up 5.4% in the past year.The commercial-stage pharmaceutical company reported a full-year loss of $11.4 million, or 47 cents a share, compared with a loss of $14.7 million, or 72 cents a share, in 2024.Revenue rose to $61.9 million, up from $56.1 million in 2024. Analysts polled by FactSet were expecting $64.6 million in revenue.Growth in revenue was driven by inaugural sales for and the commercialization of Emrosi. That was offset by competitive pressures on Accutane revenue, which fell by $6.5 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"DERM":"Journey Medical Corp"},"translate_title":"年收入低于华尔街预期后，Journey Medical股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DERM":1.5},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Journey Medical fell after the company reported 2025 revenue that missed Wall Street's expectations due to falling sales for Accutane, treatment for severe cases of acne \n\n\n  The stock was down 7.7% to $6.30 in post-market trading on Wednesday, falling deeper into negative territory after closing the regular trading session off by 1.2%. Shares are up 5.4% in the past year. \n\n\n  The commercial-stage pharmaceutical company reported a full-year loss of $11.4 million, or 47 cents a share, compared with a loss of $14.7 million, or 72 cents a share, in 2024. \n\n\n  Revenue rose to $61.9 million, up from $56.1 million in 2024. Analysts polled by FactSet were expecting $64.6 million in revenue. \n\n\n  Growth in revenue was driven by inaugural sales for and the commercialization of Emrosi. That was offset by competitive pressures on Accutane revenue, which fell by $6.5 million. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2026 18:09 ET (22:09 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}